Pride Campaigns Went Ahead Despite Bud Light and Target Controversies
Pride Month arrived on the heels of protests against LGBTQ marketing.
The Judge at the Heart of Israel’s Constitutional Crisis
In the 1990s, Chief Justice Aharon Barak led the Israeli Supreme Court in expanding the power of the judiciary. Now a controversial […]
Caeleb Dressel’s Rocky Return to Competitive Swimming
After a six-month hiatus, the seven-time Olympic gold medalist has been a shadow of himself at U.S. National Championships.
Adobe-Figma Deal Faces U.K. Scrutiny
Britain’s top competition regulator, which rejected Microsoft’s proposed acquisition of Activision, said the deal could reduce innovation and boost costs.
Consumer Spending Streak Extended in May
Consumers increased their spending for the fifth straight month in May and inflation eased, as the Federal Reserve considers whether to resume […]
What’s the Best Summer Lawn Game? Whichever One You Can Play With a Plastic Cup
Maybe you’re a volleyball family, perhaps it’s Wiffle ball season. Free advice: Don’t light the grill nearby.
Lobbyists, Guns and Miles: The Fierce Debate Over Credit Card Costs
A proposal to try to lower the fees that merchants pay on credit cards comes at a sensitive political moment for banks—but […]
Pakistan Clinches $3 Billion in IMF Rescue Lending
The International Monetary Fund program should see the cash-strapped country through its election period and installation of a new government.
Ethics Official Owned Meta Stock While Recommending FTC Chair Recuse Herself From Meta Case
The Federal Trade Commission’s designated ethics official said she acted properly, but faces questions from a watchdog group.
Brookfield Seeks Hard-to-Get Prize in American Equity Deal
Private-equity firms have been trying to buy the annuities seller for years.
Tech, Media & Telecom Roundup: Market Talk
Find insight on Disney, De La Rue and more in the latest Market Talks covering the Technology, Media and Telecom sector.
Bausch + Lomb’s New CEO Inks First Big Deal
Eye-care company has agreed to pay $1.75 billion for Novartis’s dry-eye treatment Xiidra.